FTO and BTK Inhibitors Team Up to Crush Breast Cancer Growth and Spread

Breast cancer remains the second leading cause of cancer death in women worldwide, and resistance to existing therapies—combined with high metastatic potential—highlights the urgent need for improved treatment strategies. This study focused on FTO (fat mass and obesity-associated protein), the first RNA m6A demethylase discovered, which removes N6-methyladenosine modifications from mRNA. The authors confirmed that FTO is highly expressed in breast cancer tissue and promotes tumor growth and metastasis, making it an attractive therapeutic target.

To find the best combination partner for the FTO inhibitor FB23, the team screened 27 clinically approved targeted therapy drugs across aggressive breast cancer cell lines (MDA-MB-231 and BT-549), including derivatives with enhanced lung-metastatic potential generated through serial in vivo passaging. Ibrutinib, an irreversible BTK inhibitor approved for B-cell malignancies, emerged as the top hit—producing the highest cell death rate and lowest combination index (CI), indicating strong synergy rather than simple additive effects.

RNA sequencing of treated cells revealed that the combination most potently suppressed oncogenic transcriptional programs driven by c-Myc and E2F1, two master regulators of cell cycle progression and tumor growth. Mechanistically, the drug combination increased m6A methylation on c-Myc and E2F1 mRNAs and accelerated their degradation, reducing mRNA half-life and ultimately lowering protein levels. Crucially, overexpressing c-Myc or E2F1 rescued cells from the combination's antiproliferative effects, confirming these transcription factors as key mediators of the synergy. Functional assays including CCK-8 viability, clonogenic survival, wound healing, transwell invasion, and Annexin V/PI apoptosis all demonstrated superior activity of the combination over either drug alone.

In vivo, mice bearing MDA-MB-231 xenografts showed significantly reduced tumor volume and weight when FTO was knocked down via shRNA combined with ibrutinib treatment, compared to either intervention alone. In tail-vein metastasis models using the highly lung-tropic MDA-MB-231-LMF3 line, the combination dramatically reduced lung metastatic burden and improved overall survival. Immunohistochemical analysis of tumors confirmed reduced Ki67 (proliferation), reduced FTO, c-Myc, and E2F1 expression, and increased cleaved caspase-3 (apoptosis).

The study positions combined FTO and BTK inhibition as a compelling precision oncology strategy, particularly for aggressive triple-negative breast cancer subtypes. By simultaneously targeting epigenetic RNA modification and kinase signaling, the combination circumvents common resistance mechanisms that arise with single-agent approaches. The authors call for clinical trials to evaluate FB23-ibrutinib combinations in breast cancer patients.